Global Organoids 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01252488

Publication Date:

January 28, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Organoids market size is predicted to grow from US$ 65.5 million in 2025 to US$ 187 million in 2031; it is expected to grow at a CAGR of 19.1% from 2025 to 2031.
Organoids are in-vitro derived 3D cell aggregates derived from primary tissue or stem cells that are capable of self-renewal, self-organization and exhibit organ functionality.
Organoids are a complex collection of cells grown in 3D culture medium that can summarize the various physiological and genomic characteristics of various tissues or organs. Organoids are micro-organs with three-dimensional structures that are cultivated in vitro using adult stem cells. They have highly similar genetic backgrounds and histological characteristics to organs in the body; they have complex structures similar to real organs and can partially simulate the physiological functions of the source tissues and organs; they simulate the endogenous environment to conduct research on tissue biology, development and regeneration, disease modeling, organ transplantation technology improvement, drug discovery/efficacy evaluation, and toxicology. Organoids refer to tissue analogs with a certain spatial structure formed by three-dimensional (3D) culture in vitro using adult stem cells or pluripotent stem cells. Although organoids are not true human organs, they can simulate real organs in structure and function, can simulate the structure and function of in vivo tissues to the greatest extent, and can be cultured stably for a long time (hence they are also called "micro-organs").
A major driver of the organoids market is the increasing demand for advanced models in drug discovery and personalized medicine. Organoids, which mimic the structure and function of real human organs, provide a more accurate representation of human biology compared to traditional cell cultures or animal models. This enables pharmaceutical companies to conduct more precise preclinical testing, reducing the time and cost of drug development. Additionally, organoids are being increasingly used in personalized medicine, where they can help tailor treatments to individual patients by predicting how they will respond to specific therapies, particularly in cancer research.
One of the main challenges in the organoids market is the complexity and high cost of organoid development and maintenance. Creating organoids that accurately replicate human organs requires sophisticated techniques and specialized equipment, making the process expensive and technically demanding. Additionally, there are still limitations in scaling up production and standardizing protocols, which hinders widespread adoption in clinical settings. Regulatory hurdles and the need for more validation studies to ensure the reliability of organoids in predicting human responses also pose barriers to market growth.
The 鈥淥rganoids Industry Forecast鈥� looks at past sales and reviews total world Organoids sales in 2024, providing a comprehensive analysis by region and market sector of projected Organoids sales for 2025 through 2031. With Organoids sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Organoids industry.
This Insight Report provides a comprehensive analysis of the global Organoids landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Organoids portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Organoids market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Organoids and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Organoids.
This report presents a comprehensive overview, market shares, and growth opportunities of Organoids market by product type, application, key players and key regions and countries.
Segmentation by Type:
Stem Cell Source
Tumor Cell Source
Segmentation by Application:
Precision Medicine
Pharmaceutical R&D
Academics and Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Merck
Corning
STEMCELL Technologies
Lonza
Prellis Biologics
amsbio
Tanwang Medical
Ketu Medicine
Chuangxin International

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Organoids 麻豆原创 Size (2020-2031)
2.1.2 Organoids 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Organoids by Country/Region (2020, 2024 & 2031)
2.2 Organoids Segment by Type
2.2.1 Stem Cell Source
2.2.2 Tumor Cell Source
2.3 Organoids 麻豆原创 Size by Type
2.3.1 Organoids 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Organoids 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Organoids Segment by Application
2.4.1 Precision Medicine
2.4.2 Pharmaceutical R&D
2.4.3 Academics and Research Institutes
2.5 Organoids 麻豆原创 Size by Application
2.5.1 Organoids 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Organoids 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Organoids 麻豆原创 Size by Player
3.1 Organoids 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Organoids Revenue by Player (2020-2025)
3.1.2 Global Organoids Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Organoids Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Organoids by Region
4.1 Organoids 麻豆原创 Size by Region (2020-2025)
4.2 Global Organoids Annual Revenue by Country/Region (2020-2025)
4.3 Americas Organoids 麻豆原创 Size Growth (2020-2025)
4.4 APAC Organoids 麻豆原创 Size Growth (2020-2025)
4.5 Europe Organoids 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Organoids 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Organoids 麻豆原创 Size by Country (2020-2025)
5.2 Americas Organoids 麻豆原创 Size by Type (2020-2025)
5.3 Americas Organoids 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Organoids 麻豆原创 Size by Region (2020-2025)
6.2 APAC Organoids 麻豆原创 Size by Type (2020-2025)
6.3 APAC Organoids 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Organoids 麻豆原创 Size by Country (2020-2025)
7.2 Europe Organoids 麻豆原创 Size by Type (2020-2025)
7.3 Europe Organoids 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Organoids by Region (2020-2025)
8.2 Middle East & Africa Organoids 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Organoids 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Organoids 麻豆原创 Forecast
10.1 Global Organoids Forecast by Region (2026-2031)
10.1.1 Global Organoids Forecast by Region (2026-2031)
10.1.2 Americas Organoids Forecast
10.1.3 APAC Organoids Forecast
10.1.4 Europe Organoids Forecast
10.1.5 Middle East & Africa Organoids Forecast
10.2 Americas Organoids Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Organoids Forecast
10.2.2 Canada 麻豆原创 Organoids Forecast
10.2.3 Mexico 麻豆原创 Organoids Forecast
10.2.4 Brazil 麻豆原创 Organoids Forecast
10.3 APAC Organoids Forecast by Region (2026-2031)
10.3.1 China Organoids 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Organoids Forecast
10.3.3 Korea 麻豆原创 Organoids Forecast
10.3.4 Southeast Asia 麻豆原创 Organoids Forecast
10.3.5 India 麻豆原创 Organoids Forecast
10.3.6 Australia 麻豆原创 Organoids Forecast
10.4 Europe Organoids Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Organoids Forecast
10.4.2 France 麻豆原创 Organoids Forecast
10.4.3 UK 麻豆原创 Organoids Forecast
10.4.4 Italy 麻豆原创 Organoids Forecast
10.4.5 Russia 麻豆原创 Organoids Forecast
10.5 Middle East & Africa Organoids Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Organoids Forecast
10.5.2 South Africa 麻豆原创 Organoids Forecast
10.5.3 Israel 麻豆原创 Organoids Forecast
10.5.4 Turkey 麻豆原创 Organoids Forecast
10.6 Global Organoids Forecast by Type (2026-2031)
10.7 Global Organoids Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Organoids Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Organoids Product Offered
11.1.3 Thermo Fisher Scientific Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Organoids Product Offered
11.2.3 Merck Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 Corning
11.3.1 Corning Company Information
11.3.2 Corning Organoids Product Offered
11.3.3 Corning Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Corning Main Business Overview
11.3.5 Corning Latest Developments
11.4 STEMCELL Technologies
11.4.1 STEMCELL Technologies Company Information
11.4.2 STEMCELL Technologies Organoids Product Offered
11.4.3 STEMCELL Technologies Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 STEMCELL Technologies Main Business Overview
11.4.5 STEMCELL Technologies Latest Developments
11.5 Lonza
11.5.1 Lonza Company Information
11.5.2 Lonza Organoids Product Offered
11.5.3 Lonza Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Lonza Main Business Overview
11.5.5 Lonza Latest Developments
11.6 Prellis Biologics
11.6.1 Prellis Biologics Company Information
11.6.2 Prellis Biologics Organoids Product Offered
11.6.3 Prellis Biologics Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Prellis Biologics Main Business Overview
11.6.5 Prellis Biologics Latest Developments
11.7 amsbio
11.7.1 amsbio Company Information
11.7.2 amsbio Organoids Product Offered
11.7.3 amsbio Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 amsbio Main Business Overview
11.7.5 amsbio Latest Developments
11.8 Tanwang Medical
11.8.1 Tanwang Medical Company Information
11.8.2 Tanwang Medical Organoids Product Offered
11.8.3 Tanwang Medical Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Tanwang Medical Main Business Overview
11.8.5 Tanwang Medical Latest Developments
11.9 Ketu Medicine
11.9.1 Ketu Medicine Company Information
11.9.2 Ketu Medicine Organoids Product Offered
11.9.3 Ketu Medicine Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Ketu Medicine Main Business Overview
11.9.5 Ketu Medicine Latest Developments
11.10 Chuangxin International
11.10.1 Chuangxin International Company Information
11.10.2 Chuangxin International Organoids Product Offered
11.10.3 Chuangxin International Organoids Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Chuangxin International Main Business Overview
11.10.5 Chuangxin International Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.